Guidance on medical physics expert support for nuclear medicine.


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
01 Jul 2022
Historique:
pubmed: 24 5 2022
medline: 23 6 2022
entrez: 23 5 2022
Statut: ppublish

Résumé

The Ionising Radiation (Medical Exposure) Regulations require employers to appoint suitable medical physics experts (MPE) for nuclear medicine services, and they also define the areas where MPEs are required to provide advice and specify matters that they must contribute towards. Applications for employer licences under IR(ME)R require employers to specify the level of MPE support available and if this is provided by onsite MPEs or remotely. Assessment of these applications by the Administration of Radioactive Substances Advisory Committee (ARSAC) has highlighted variability in the levels of MPE support being provided for similar services across the UK. A working party including representatives from IPEM, ARSAC, BIR and BNMS was formed and has produced these recommendations on MPE support. Nuclear medicine services were divided into seven broad categories and MPE support for each category has been considered. However, some services that differ from the scenarios provided in this guidance may require different levels of MPE support. Positron emission tomography (PET)/CT and gamma camera imaging have been considered separately here, although it is recognised that both PET/CT and gamma cameras are often sited within the same department in many centres. The separation has been done for pragmatic purposes, as there are felt to be sufficient differences in the MPE role requirements. This guidance sets out recommendations for MPE support, and broader physics support, to run a safe nuclear medicine service and defines the responsibilities of these staff for a range of clinical nuclear medicine services. The recommendations on MPE support made are advice, but will assist employers in meeting regulatory requirements.

Identifiants

pubmed: 35604659
doi: 10.1259/bjr.20211393
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20211393

Auteurs

Louise Fraser (L)

Medical Exposures Group, UK Health Security Agency, Representing ARSAC Secretariat, England, United Kingdom.

Nasreen Parkar (N)

Medical Exposures Group, UK Health Security Agency, Representing ARSAC Secretariat, England, United Kingdom.

Kathryn Adamson (K)

Nuclear Medicine, Guy's and St Thomas' NHS Foundation Trust, Representing ARSAC, England, United Kingdom.

Alison Fletcher (A)

Nuclear Medicine Physics, NHS Lothian, Representing IPEM, Edinburgh, United Kingdom.

Peter Julyan (P)

Nuclear Medicine, The Christie NHS Foundation Trust, Representing ARSAC, England, United Kingdom.

Charnie Kalirai (C)

Department of Medical Physics and Clinical Engineering, Nuclear Medicine, Nottingham University Hospitals NHS Trust, Representing BNMS, England, United Kingdom.

Daniel McGowan (D)

Department of Medical Physics and Clinical Engineering, Oxford University Hospitals NHS Foundation Trust, Representing BIR, England, United Kingdom.

Fergus McKiddie (F)

Nuclear Medicine, NHS Grampian, Aberdeen, Representing IPEM, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH